|Bid||29.00 x 800|
|Ask||37.00 x 800|
|Day's range||30.24 - 35.79|
|52-week range||15.58 - 78.58|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
FRIENDSWOOD, Texas, August 08, 2022--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter and six months ended June 30, 2022.
FRIENDSWOOD, Texas, August 04, 2022--Castle announced that the AGA published an update article stating that TissueCypher® may be beneficial for risk-stratification of patients with NDBE.
FRIENDSWOOD, Texas, August 03, 2022--Castle will present a company overview at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, Aug. 10, 2022, at 1:00 p.m. Eastern time